Neuroendocrine Tumors - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Neuroendocrine Tumors - Pipeline Review, H1 2016

Neuroendocrine Tumors - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Neuroendocrine Tumors - Pipeline Review, H1 2016
Published May 31, 2016
304 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Neuroendocrine Tumors - Pipeline Review, H1 2016, provides an overview of the Neuroendocrine Tumors pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects
- The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumo

  
Source:
Document ID
GMDHC8174IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Neuroendocrine Tumors Overview121
Therapeutics Development132
  Pipeline Products for Neuroendocrine Tumors Overview131
  Pipeline Products for Neuroendocrine Tumors Comparative Analysis141
Neuroendocrine Tumors Therapeutics under Development by Companies152
Neuroendocrine Tumors Therapeutics under Investigation by Universities/Institutes171
Neuroendocrine Tumors Pipeline Products Glance183
  Late Stage Products181
  Clinical Stage Products191
  Early Stage Products201
Neuroendocrine Tumors Products under Development by Companies213
Neuroendocrine Tumors Products under Investigation by Universities/Institutes241
Neuroendocrine Tumors Companies Involved in Therapeutics Development2535
  Advanced Accelerator Applications S.A.251
  Aegis Therapeutics, LLC261
  Amgen Inc.271
  AVEO Pharmaceuticals, Inc.281
  Boehringer Ingelheim GmbH291
  Chiasma, Inc.301
  Crinetics Pharmaceuticals, Inc.311
  Daiichi Sankyo Company, Limited321
  Delcath Systems, Inc.331
  DexTech Medical AB341
  Eisai Co., Ltd.351
  Exelixis, Inc.361
  Foresee Pharmaceuticals, LLC371
  Hutchison MediPharma Limited381
  Intezyne, Inc391
  INVENT Pharmaceuticals, Inc.401
  Ipsen S.A.411
  Jiangsu Hengrui Medicine Co., Ltd.421
  Karyopharm Therapeutics, Inc.431
  Lexicon Pharmaceuticals, Inc.441
  Midatech Pharma Plc451
  Millennium Pharmaceuticals, Inc.461
  MolMed S.p.A.471
  Northwest Biotherapeutics, Inc.481
  Novartis AG491
  OctreoPharm Sciences GmbH501
  OXiGENE, Inc.511
  Peptron, Inc.521
  Pfizer Inc.531
  Pharma Mar, S.A.541
  Progenics Pharmaceuticals, Inc.551
  Provectus Biopharmaceuticals, Inc.561
  Sompharmaceuticals S.A.571
  Strongbridge Biopharma plc581
  Vascular Biogenics Ltd.591
Neuroendocrine Tumors Therapeutics Assessment6012
  Assessment by Monotherapy Products601
  Assessment by Target614
  Assessment by Mechanism of Action653
  Assessment by Route of Administration682
  Assessment by Molecule Type702
Drug Profiles72120
  AV-203 - Drug Profile721
    Product Description721
    Mechanism of Action721
    R&D Progress722
  axitinib - Drug Profile741
    Product Description741
    Mechanism of Action741
    R&D Progress744
  cabozantinib s-malate - Drug Profile781
    Product Description781
    Mechanism of Action781
    R&D Progress785
  COR-005 - Drug Profile831
    Product Description831
    Mechanism of Action831
    R&D Progress833
  DCVax-Direct - Drug Profile861
    Product Description861
    Mechanism of Action861
    R&D Progress861
  DS-6051 - Drug Profile871
    Product Description871
    Mechanism of Action871
    R&D Progress871
  E-7449 - Drug Profile881
    Product Description881
    Mechanism of Action881
    R&D Progress881
  Edotreotide Labeled Yttrium 90 - Drug Profile891
    Product Description891
    Mechanism of Action891
    R&D Progress892
  everolimus - Drug Profile911
    Product Description911
    Mechanism of Action911
    R&D Progress917
  fosbretabulin tromethamine - Drug Profile981
    Product Description981
    Mechanism of Action981
    R&D Progress984
  FP-002 - Drug Profile1021
    Product Description1021
    Mechanism of Action1021
    R&D Progress1021
  G-02113 - Drug Profile1031
    Product Description1031
    Mechanism of Action1031
    R&D Progress1031
  ganitumab - Drug Profile1041
    Product Description1041
    Mechanism of Action1041
    R&D Progress1043
  HMPL-012 - Drug Profile1071
    Product Description1071
    Mechanism of Action1071
    R&D Progress1072
  INV-440 - Drug Profile1091
    Product Description1091
    Mechanism of Action1091
    R&D Progress1091
  iobenguane sulfate I 131 - Drug Profile1101
    Product Description1101
    Mechanism of Action1101
    R&D Progress1102
  IT-139 - Drug Profile1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1121
  L-779976 - Drug Profile1131
    Product Description1131
    Mechanism of Action1131
    R&D Progress1132
  lanreotide acetate - Drug Profile1151
    Product Description1151
    Mechanism of Action1151
    R&D Progress1152
  lurbinectedin - Drug Profile1171
    Product Description1171
    Mechanism of Action1171
    R&D Progress1174
  Lutathera - Drug Profile1211
    Product Description1211
    Mechanism of Action1211
    R&D Progress1213
  lutetium (177Lu) edotreotide - Drug Profile1241
    Product Description1241
    Mechanism of Action1241
    R&D Progress1241
  melphalan - Drug Profile1251
    Product Description1251
    Mechanism of Action1251
    R&D Progress1253
  netazepide - Drug Profile1281
    Product Description1281
    Mechanism of Action1281
    R&D Progress1282
  NGR-hTNF - Drug Profile1301
    Product Description1301
    Mechanism of Action1301
    R&D Progress1304
  nintedanib - Drug Profile1341
    Product Description1341
    Mechanism of Action1341
    R&D Progress1346
  Novaferon - Drug Profile1401
    Product Description1401
    Mechanism of Action1401
    R&D Progress1402
  octreotide acetate - Drug Profile1421
    Product Description1421
    Mechanism of Action1421
    R&D Progress1423
  octreotide acetate - Drug Profile1451
    Product Description1451
    Mechanism of Action1451
    R&D Progress1451
  octreotide acetate long acting - Drug Profile1461
    Product Description1461
    Mechanism of Action1461
    R&D Progress1462
  octreotide acetate SR - Drug Profile1481
    Product Description1481
    Mechanism of Action1481
    R&D Progress1481
  octreotide SR - Drug Profile1491
    Product Description1491
    Mechanism of Action1491
    R&D Progress1491
  ofranergene obadenovec - Drug Profile1501
    Product Description1501
    Mechanism of Action1501
    R&D Progress1502
  OPS-201 - Drug Profile1521
    Product Description1521
    Mechanism of Action1521
    R&D Progress1521
  panobinostat - Drug Profile1531
    Product Description1531
    Mechanism of Action1531
    R&D Progress1537
  PV-10 - Drug Profile1601
    Product Description1601
    Mechanism of Action1601
    R&D Progress1605
  ribociclib succinate - Drug Profile1651
    Product Description1651
    Mechanism of Action1651
    R&D Progress1653
  RRX-001 - Drug Profile1681
    Product Description1681
    Mechanism of Action1681
    R&D Progress1682
  rSIFN-co - Drug Profile1701
    Product Description1701
    Mechanism of Action1701
    R&D Progress1701
  sapanisertib - Drug Profile1711
    Product Description1711
    Mechanism of Action1711
    R&D Progress1712
  selinexor - Drug Profile1731
    Product Description1731
    Mechanism of Action1731
    R&D Progress1736
  SHR-1020 - Drug Profile1791
    Product Description1791
    Mechanism of Action1791
    R&D Progress1792
  Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile1811
    Product Description1811
    Mechanism of Action1811
    R&D Progress1811
  Somadex - Drug Profile1821
    Product Description1821
    Mechanism of Action1821
    R&D Progress1821
  sunitinib malate - Drug Profile1831
    Product Description1831
    Mechanism of Action1831
    R&D Progress1835
  Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile1881
    Product Description1881
    Mechanism of Action1881
    R&D Progress1881
  telotristat etiprate - Drug Profile1891
    Product Description1891
    Mechanism of Action1891
    R&D Progress1892
  TR-2A - Drug Profile1911
    Product Description1911

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Neuroendocrine Tumors - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neuroendocrine-Tumors-Pipeline-Review-H1-2016-2088-15912>
  
APA:
Global Markets Direct - Market Research. (2016). Neuroendocrine Tumors - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neuroendocrine-Tumors-Pipeline-Review-H1-2016-2088-15912>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.